Navigation Links
Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference
Date:2/27/2012

SAN DIEGO, Feb. 27, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 32nd Annual Cowen Health Care Conference on Wednesday, March 7 at 8:40 AM Eastern Time in Boston, MA.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO )

A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com.  Replays of the presentation will be available at the same location for 90 days following the presentation.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR™. The company is seeking marketing authorization for fidaxomicin in Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.

Contacts

Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-909-0736
Dwalsey@optimerpharma.com

Canale Communications
Jason I. Spark, Senior Vice President
619-849-
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
2. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
3. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
4. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
5. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
6. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
7. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
8. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
9. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
10. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
11. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by AstraZeneca plc, quetiapine ... important drug for the treatment of schizophrenia. Approved ... was listed in the Catalogue of Drugs for ...
(Date:8/28/2015)... 28, 2015 The scientific team of ... one of the leading academics in the field of aging ... holder in life extension for model animals - 10 fold ... aging and age-related diseases, primarily, around the stability and stress ... been published as "Stability analysis of a model gene network ...
(Date:8/28/2015)... and ATLANTA , August 28, 2015 ... Food and Drug Administration (FDA) cleared the MagVita TMS Therapy ... patients who have failed to receive satisfactory improvement from prior ... technique for stimulating neural tissue in the part of the ... procedure has been proven safe and effective and MagVenture is ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3
... Colo., Oct. 17 Pharmion Corporation,(Nasdaq: PHRM ... pivotal,Phase 3 clinical trial evaluating amrubicin, the Company,s ... cell lung,cancer (SCLC). The randomized, controlled, multi-center study ... for second-line,treatment of SCLC in the US and ...
... and Bare ... Metal Stents, ... Adjudication Study) trial of OrbusNeich,s,Genous Bio-engineered R stent has reached 110 ... de Winter, M.D., Ph.D.,principal investigator and director of the catheterization laboratory ...
Cached Medicine Technology:Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer 2Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer 3Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer 4Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer 5Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) 2
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL —Pocket ... zero fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. ... SupplySide CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were ...
(Date:8/28/2015)... ... 2015 , ... The Nashville Business Journal recently announced its ... Mr. Troy Mizell, Chairman of the Board at MyGenetx, is one of ... Awards will recognize Nashville military veterans who, through their professional and personal efforts, ...
(Date:8/28/2015)... ... August 28, 2015 , ... Northridge dentists Dr. ... whitening. For just $199, patients can currently receive a one hour treatment of this ... procedures, but it includes a number of unique features that can turn teeth up ...
(Date:8/28/2015)... ... August 28, 2015 , ... The newest therapy to receive orphan drug ... use any time soon, according to educational website Surviving Mesothelioma. Click here to ... drug designation for mesothelioma last week from the FDA, will now head into Phase ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... now consolidated as MDL 2545, Testosterone Replacement Therapy Products Liability Litigation, are in ... number of custodial files the PSC may receive for corporate employees involved in ...
Breaking Medicine News(10 mins):Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4
... finds , , WEDNESDAY, Nov. 19 (HealthDay News) -- ... is roughly the same no matter what the patient,s ... disparities in our health care system have been well ... artery disease, congestive heart failure, renal failure, acute appendicitis ...
... Rendell today revised his July 8 executive order extending the ... Under the revised order, the council will remain in operation ... the council, whichever occurs first. , ... PHC4 was allowed to "sunset" by the General Assembly. It ...
... Educate Health Care Stakeholders , ... The Virginia Business Coalition on Health (VBCH) announced its ... efforts initiated by the Center for Medicare and Medicaid ... Events" - serious and costly preventable hospital errors. Effective ...
... Leaves Skin Consistently Smooth and Visibly Tight , ... Body-sculpting technology with consistently smooth, visibly tight results ... now available to those who want effective body reshaping ... leader in aesthetic body shaping technology, SmoothLipo is a ...
... Nov. 19 (HealthDay News) -- The dietary supplement beta-alanine ... -- improves muscle endurance in the elderly, according to ... the prevention of falls, and the maintenance of health ... study author Jeffrey Stout of the University of Oklahoma. ...
... Researchers at Southern Methodist University in Dallas are pioneering ... scan data from Persian Gulf War veterans, aiming to ... Gulf War Syndrome. , Richard Gunst, Wayne Woodward and ... collaborating with imaging specialists at UT Southwestern Medical Center ...
Cached Medicine News:Health News:Patient's Race Doesn't Affect Emergency Room Care 2Health News:Governor Rendell Revises Executive Order; Extends Operation of PA Health Care Cost Containment Council 2Health News:Governor Rendell Revises Executive Order; Extends Operation of PA Health Care Cost Containment Council 3Health News:Virginia Business Coalition on Health Issues Statement of Support for Hospital Improvement 2Health News:Virginia Business Coalition on Health Issues Statement of Support for Hospital Improvement 3Health News:Eleme Medical Launches SmoothLipo(TM) Body Shaping Treatment 2Health News:Deep brain mapping to isolate evidence of Gulf War syndrome 2
... ICP Monitoring System provides ... intracranial pressure at the ... levels. The information is ... through a hydrostatic column ...
The Optical Tracking System provides a complete solution for image-guided surgery. Precision tracking technology converges with powerful visualization software for optimal surgical planning and navig...
Penfield Dissector #2...
ScalpFix scalp clip system includes an reusable handle, scalp clips, sterile packed cartridges and removal forceps. It is easy to use, time saving and fast application....
Medicine Products: